Related Experiment Videos
Brain-specific proteins: solid-phase immunobioluminescence assay for neuron-specific enolase in human plasma
Clinical Chemistry
|March 1, 1984
Summary
This study developed a specific antibody assay to measure alpha alpha- and gamma gamma-enolase isoenzymes in human plasma. The assay enables precise detection of these enzymes, aiding in cancer diagnostics.
Area of Science:
- Biochemistry
- Immunology
- Enzymology
Background:
- Enolase (EC 4.2.1.11) exists as different isoenzymes, including alpha alpha- and gamma gamma-forms, primarily found in human brain.
- Accurate quantification of these isoenzymes in biological samples is crucial for diagnostic purposes, particularly in oncology.
Purpose of the Study:
- To develop and validate a highly specific immunoassay for quantifying alpha alpha- and gamma gamma-enolase isoenzymes in human plasma.
- To assess the utility of this assay in measuring enolase isoenzyme activities in patients with malignant tumors.
Main Methods:
- Generation of specific rabbit antibodies against purified human brain alpha alpha- and gamma gamma-enolase isoenzymes.
- Immunoabsorption and desorption of antibodies, followed by coating onto polystyrene tubes for assay development.
- Quantification of enolase isoenzyme activity using a firefly luciferase bioluminescence system to measure ATP accumulation.
Main Results:
- The developed immunoassay demonstrated high specificity, directly correlating with the antibodies used for coating.
- The assay achieved a low detection limit of approximately 5 X 10(-9) U (0.1 pg or 10(-18) mol of enzyme protein).
- The assay allowed for separate, rapid, and precise evaluation of enolase isoenzyme activities in human plasma.
Conclusions:
- A novel, highly sensitive, and specific immunoassay for human enolase isoenzymes has been successfully developed.
- This assay is suitable for the precise measurement of enolase isoenzyme activities in human plasma.
- The assay holds potential for application in the diagnosis and monitoring of malignant tumors by analyzing plasma enolase isoenzyme profiles.